-
Welcome to New Orleans for the Scientific Sessions
The dynamic four-day program developed by this year’s Scientific Sessions Planning Committee is packed with scientific discovery, clinical innovation, networking channels, and more for researchers and healthcare professionals dedicated to advancing the prevention, treatment, care, and the long-sought cure for diabetes.
-
Obesity Year in Review to give an overview of major advances and discoveries
Presentations in this opening-day symposium will include a review of recent literature on the clinical application of glucagon-like peptide-1 (GLP-1)-based drugs by Julio E. Ayala, PhD, who will also identify knowledge gaps that can guide future clinical trials.
Scientific Sessions Newsmakers
-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
-
Session to provide updates on MASLD, lipoprotein biology, and CV risk
Panelists will discuss an underexplored nexus of metabolic dysfunction in diabetes on the final day of the 2026 Scientific Sessions. Scott Summers, PhD, will explore the role of ceramides in metabolic dysfunction-associated steatotic liver disease and cardiovascular risk. Other topics include cholesterol, clot lysis, and thrombosis.
-
Hot topics in nutrition for 2026: menopause, ultraprocessed foods, misinformation, and care delivery for immigrant populations
Presenters, including Hillary Wright, MEd, RDN, LDN, will discuss trending topics in nutrition and how food choices and other factors affect individuals living with diabetes across different ages and ethnicities.
-
Debate to focus on BMI and definitions of obesity
Body mass index (BMI) is one of the most controversial topics in the assessment of obesity today. Session Chair Robert Kushner, MD, previews a debate on whether this metric should be the primary tool in defining obesity.
-
Panel discussion to track diabetes across diverse populations in the U.S.
Jithin Sam Varghese, PhD, MTech, and other panelists will delve into the epidemiology of diabetes, social roadblocks, and variations in health outcomes across the country amid changing national demographics.
-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
Presenter Profiles
